Optithera specializes in precision medicine, focusing on the development of innovative technologies to predict complications associated with type 2 diabetes. The company has created a unique, non-invasive test that utilizes a saliva sample to analyze an individual's genetic profile. This analysis employs artificial intelligence to generate a polygenic risk score, which assesses the likelihood of developing complications such as kidney disease, heart disease, and cerebrovascular issues. By considering factors like gender, age of onset, and ethnicity, the test aims to identify risks early, allowing healthcare professionals to establish tailored treatment plans for patients.

The research and development efforts at Optithera are supported by significant funding from organizations like Genome Canada, which emphasizes the importance of genomics in addressing health challenges. The company has conducted extensive studies involving over 20,000 type 2 diabetes patients across multiple countries, contributing to a deeper understanding of the genetic factors influencing diabetes complications. This commitment to advancing genomics and precision medicine positions Optithera as a leader in the field, with a mission to enhance patient outcomes through early risk assessment and personalized healthcare strategies.

Canada

OPTITHERA was founded in 2016 and has analyzed data from more than 20,000 type 2 diabetes patients from 20 countries. Based on these clinical studies and with the help of artificial intelligence, researchers were able to develop a genome test that can inform your physician if you are at risk of developing complications related to type 2 diabetes.

Optithera

Company Details